ArticlePathogens (Basel, Switzerland)2022
Taking a Promising Vaccine Candidate Further: Efficacy of ASFV-G-ΔMGF after Intramuscular Vaccination of Domestic Pigs and Oral Vaccination of Wild Boar.
Article in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 30 citations in OpenAlex.
- Article
- African swine fever virus genes vectored by simian adenoviruses do not protect against virulent genotype II virus challenge.Microbiology spectrum · 2026Article
- The Prospects and Challenges of Live Attenuated Vaccines Against African Swine Fever Virus in Vietnam.Vaccines · 2026Review
- Duration of immunity following infection with moderately virulent ASFV.PLoS pathogens · 2026Article
- Oral Bait Immunization of Eurasian Wild Boar (Vaccines · 2026Article
- Hope and hurdles: unlocking the potential of modified live virus vaccines for African swine fever.Emerging microbes & infections · 2025Review
- Insights and progress on epidemic characteristics, pathogenesis, and preventive measures of African swine fever virus: A review.Virulence · 2025Review
- Article
- Review
- African swine fever: A highly fatal disease that is spreading globally.Open veterinary journal · 2025Review
- Mitigation Strategies for African Swine Fever Virus Biosecurity: From Virus Inactivation to Pig Health.Transboundary and emerging diseases · 2025Review
- Safety and Efficacy Profiles of the Live Attenuated Vaccine AVAC ASF LIVE for Preventing African Swine Fever in Pigs.Transboundary and emerging diseases · 2025Article
- Safety of Live Attenuated ASFV-G-ΔI177L/ΔLVR Vaccination in Sows With Advanced Pregnancies.Transboundary and emerging diseases · 2025Article
- Maternal immunity and African swine fever virus: understanding the limits of passive protection.Frontiers in immunology · 2025Article
- Article
- Article
- Article
- Towards Safe African Swine Fever Vaccines: TheAnimals : an open access journal from MDPI · 2024Article
- Review
- Recombinant Vaccine Strain ASFV-G-Δ9GL/ΔUK Produced in the IPKM Cell Line Is Genetically Stable and Efficacious in Inducing Protection in Pigs Challenged with the Virulent African Swine Fever Virus Field Isolate Georgia 2010.Pathogens (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
African swine fever (ASF) is a pandemic threat to the global pig industry and wild suids. A safe and efficacious vaccine could monumentally assist in disease eradication. In the past years, promising live attenuated vaccine candidates emerged in proof-of-concept experiments, among which was "ASFV-G-∆MGF". In our study, we tested the vaccine candidate in three animal experiments intramuscularly in domestic pigs and orally in wild boar. Further, a macrophage-grown vaccine virus and a virus grown on permanent cells could be employed. Irrespective of the production system of the vaccine virus, a two-dose intramuscular immunization could induce close-to-sterile immunity with full clinical protection against challenge infection. After oral immunization, 50% of the vaccinees seroconverted and all responders were completely protected against subsequent challenge. All nonresponders developed ASF upon challenge with two acute lethal infections and two mild and transient courses. The latter results show a lower efficiency after oral administration that would have to be taken into consideration when designing vaccination-based control measures. Overall, our findings confirm that "ASFV-G-∆MGF" is a most promising vaccine candidate that could find its way into well-organized and controlled immunization campaigns. Further research is needed to characterize safety aspects and define possible improvements of oral efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.